FMFredric Manfredsson

Fredric Manfredsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fredric Manfredsson has a total of 330 co-authors. Here are the top co-authors by number of shared publications:

  • Ivette M. Sandoval

    Barrow Neurological Institute

    17 shared publications
  • Keqiang Ye

    Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China

    9 shared publications
  • Kathy Steece-Collier

    Department of Translational Neuroscience, Michigan State University College of Human Medicine, Grand Rapids, MI 49506, USA

    8 shared publications
  • Matthew J. Benskey

    Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA

    7 shared publications
  • Xia Liu

    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

    7 shared publications
  • Christopher Bishop

    Department of Psychology, Binghamton University, Binghamton, NY 13902, USA

    5 shared publications

Latest Publications

  • Open Access

    Dual kinase inhibition provides early clues to restoration of neuroimmune homeostasis in an AAV-haSyn model of Parkinsons disease

    by Wesley Chiang, Ivette M. Sandoval, Herman Li, Luis Daniel Bernal-Conde, Rene Squire, Madeline K. Washburn, Jack L. Schwartz, Erica Squire, Eric J. Wagner, Fredric P. Manfredsson, et al.

    Background Previous studies of drugs targeting mixed linage kinase type 3 (MLK3) and/or leucine rich repeat kinase type 2 (LRRK2) in sporadic Parkinsons disease (PD) have failed to meet clinical endpoints despite multiple lines of evidence implicating these kinases in pathogenesis. This has reduced enthusiasm for MLK3 and LRRK2 as druggable targets. Largely overlooked is the evidence that these targets remain valid but must be considered in combination to achieve a therapeutic outcome. This provides the rationale for this study. Methods We conducted a pilot study modeling early, pre-symptomatic PD with subsequent evaluation of therapeutic potential of a multi-kinase inhibitor (URMC-099) in alleviating disease pathology. Sprague Dawley rats received unilateral intranigral injections of low dose AAV-haSyn. After a two-week recovery period, all animals were administered either once-daily intraperitoneal (i.p.) injection of URMC-099 or its vehicle control until their terminal endpoint. Induction of early PD, and its alleviation with URMC-099, was evaluated by lateralized motor impairment using the cylinder test and immunohistochemical analysis of neuropathology in the substantia nigra (SN) and striatum. Finally, an in vitro microglial PD model exposed to aSyn pre-formed fibrils and treated with URMC-099 was used to further evaluate the mechanism underlying therapeutic activity. Results A unilateral model of early and progressive AAV-haSyn model for PD was used to demonstrate the therapeutic potential of a targeted multi-kinase inhibitor to attenuate PD-associated neuropathology and prevent the manifestation of lateral motor deficits. Immunohistochemical analysis revealed protection of neuronal cellular integrity along the nigral-striatal pathway with once-daily i.p. URMC-099. The mitigation of degenerative neuropathology was linked to targeted inhibition of MLK3 and LRRK2 and complemented by reduced levels of gliosis in astrocytes and microglia in the SN. Single-microglia segmentation analysis suggested URMC-099 treatment preserved dynamic effector state switching in microglia to enhance autophagic flux to reduce the overall burden of pathologic aSyn. Transcriptomic analysis of a complementary in vitro microglia model corroborated the retention of a homeostatic-like effector state with URMC-099 treatment that was unique to MLK3/LRRK2 dual inhibition. Conclusions Unilateral injection of low dose AAV-haSyn successfully resulted in a lateralized model of early, progressive PD. Dual inhibition of aberrant MLK3 and LRRK2 activity with once-daily i.p. URMC-099 therapy significantly mitigated the development of PD pathology and progression in an early manifest phenotype. Our results present a potential mechanism of therapeutic action dependent on the dual inhibition of MLK3 and LRRK2. This presents a novel therapeutic modality that may be beneficial to a broad population of etiologic PD patients.

  • Open Access

    Effects of chemogenetic inhibition of serotonergic raphe-striatal neurons on L-DOPA-induced behaviors and neurochemistry in a rat model of Parkinson’s disease

    by Carla N. Budrow, Luis-Daniel Bernal-Conde, Ivette M. Sandoval, Ashley Galfano, Han Grezenko, Angela Velazquez, David J. Marmion, Eden Flores-Barrera, Shruti Venkatesh, Michael Coyle, et al.

    The online version contains supplementary material available at 10.1186/s40478-026-02221-1. The online version contains supplementary material available at 10.1186/s40478-026-02221-1.


  • Gene therapy for Parkinson’s disease—Ample room for optimism

    by Ivette M. Sandoval, Michael F. Salvatore, Fredric P. Manfredsson


  • Open Access

    Devaluing memories of reward: a case for dopamine

    by Benjamin R. Fry, Nicolette Russell, Victoria Fex, Bing Mo, Nathan Pence, Joseph A. Beatty, Fredric P. Manfredsson, Brandon A. Toth, Christian R. Burgess, Samuel Gershman, et al.

    Midbrain dopamine cells encode differences in predictive and expected value to support learning through reward prediction error. Recent findings have questioned whether reward prediction error can fully account for dopamine function and suggest a more complex role for dopamine in encoding detailed features of the reward environment. In this series of studies, we describe a novel role for dopamine in devaluing sensory features of reward. Mesencephalic dopamine cells activated during a mediated devaluation phase were later chemogenetically reactivated. This retrieval of the devalued reward memory elicited a reduction in the hedonic evaluation of sucrose reward. Through optogenetic and chemogenetic manipulations, we confirm dopamine cells are both sufficient and necessary for mediated devaluation, and retrieval of these memories reflected dopamine release in the nucleus accumbens. Consistent with our computational modeling data, our findings indicate a critical role for dopamine in encoding predictive representations of the sensory features of reinforcement. Overall, we elucidate a novel role for dopamine function in mediated devaluation and illuminate a more elaborate framework through which dopamine encodes reinforcement signals.


  • Assessment of complementary white matter microstructural changes and grey matter atrophy in the 6-OHDA-induced model of Parkinson’s disease

    by Maurizio Bergamino, Alberto Fuentes, Ivette M. Sandoval, David J. Marmion, Christopher Bishop, Fredric P. Manfredsson, Ashley M. Stokes


  • Effects of genetic knockdown of the serotonin transporter on established L-DOPA-induced dyskinesia and gene expression in hemiparkinsonian rats

    by Grace McManus, Ashley Galfano, Carla Budrow, Natalie Lipari, Kuei Y. Tseng, Fredric P. Manfredsson, Christopher Bishop


  • Open Access

    Tau, amyloid-β and α-synuclein co-pathologies synergistically enhance neuroinflammation and neuropathology

    by Jhodi M. Webster, Ya-Ting Yang, Aidan T. Miller, Asta Zane, Kasandra Scholz, William J. Stone, Nikhita Mudium, Nicole J. Corbin-Stein, Woong-Jai Won, Anna C. Stoll, et al.

    Alzheimer’s (AD) and Parkinson disease (PD) pathology often co-occur. Amyloid-β and phosphorylated tau are found in 30-50% of idiopathic PD cases, while α-synuclein inclusions are present in 50% of AD cases. These co-pathologies are linked to increased mortality and earlier onset of cognitive decline. Immune activation is a hallmark of these neurodegenerative diseases, but current models primarily examine each pathology in isolation. How these co-pathologies drive inflammation and neuronal loss remains poorly understood. We therefore developed a mouse model combining tau, amyloid-β, and α-synuclein. We found that co-pathologies synergistically trigger an amplified neuroimmune response, with expanded populations of CD4 + and CD8 + tissue-resident memory T cells and CD68 + microglia, compared to single pathologies. These changes were abundant in the hippocampus and cortex, regions with elevated protein pathology load and enhanced neuronal loss. Our findings demonstrate that co-pathologies enhance proteinopathy and synergistically enhance immune activation and neurodegeneration, suggesting that combinatorial therapeutic strategies that target both co-pathologies and inflammation, may be disease modifying. Summary: Webster et al. demonstrate that co-occurring Alzheimer’s and Parkinson disease protein pathologies, common in cognitively impaired patient populations, amplify proteinopathy and synergistically enhance CNS neuroinflammatory responses and neurodegeneration. This work supports the need for combinatorial therapeutic strategies and positions neuroinflammation as an important link for co-pathology enhanced neurodegeneration.


  • Open Access

    Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS

    by Ivette M. Sandoval, Christy M. Kelley, Luis Daniel Bernal-Conde, Kathy Steece-Collier, David J. Marmion, Marcus Davidsson, Sean M. Crosson, Sanford L. Boye, Shannon E. Boye, Fredric P. Manfredsson


  • Open Access

    Tissue resident memory CD8+ T cells are present but not critical for demyelination and neurodegeneration in a mouse model of multiple system atrophy

    by Nicole J. Corbin-Stein, Gabrielle M. Childers, Jhodi M. Webster, Asta Zane, Ya-Ting Yang, Akkas Ali, Ivette M. Sandoval, Fredric P. Manfredsson, Jeffrey H. Kordower, Daniel J. Tyrrell, et al.

    Multiple system atrophy (MSA) is rare, fast progressing, and fatal synucleinopathy with alpha-synuclein (α-syn) inclusions located within oligodendroglia called glial cytoplasmic inclusions (GCI). Along with GCI pathology there is severe demyelination, neurodegeneration, and neuroinflammation. In post-mortem tissue, there is significant infiltration of CD8+ T cells into the brain parenchyma, however their role in disease progression is unknown. To determine the role of CD8+ T cells, a modified AAV, Olig001-SYN, was used to selectively overexpress α-syn in oligodendrocytes modeling MSA in mice. Four weeks post transduction, we observed significant CD8+ T cell infiltration into the striatum of Olig001-SYN transduced mice recapitulating the CD8+ T cell infiltration observed in post-mortem tissue. To understand the role of CD8+ T cells, a CD8 knockout mice were transduced with Olig001-SYN. Six months post transduction into a mouse lacking CD8+ T cells, demyelination and neurodegeneration were unchanged. Four weeks post transduction, neuroinflammation and demyelination were enhanced in CD8 knockout mice compared to wild type controls. Applying unbiased spectral flow cytometry, CD103+, CD69+, CD44+, CXCR6+, CD8+ T cells were identified when α-syn was present in oligodendrocytes, suggesting the presence of tissue resident memory CD8+ T (Trm) cells during MSA disease progression. This study indicates that CD8+ T cells are not critical in driving MSA pathology but are needed to modulate the neuroinflammation and demyelination response.


  • Open Access

    Engineered Nanobodies With Programmable Target Antigen Proteolysis (Ptap) Fusions Regulate Intracellular Alpha-synuclein in Vitro and in Vivo

    by Jeffrey Kordower, David Butler, Diptaman Chatterjee, Lianna D'Brant, Benjamin Hiller, David Marmion, Ivette Sandoval, Kelvin Luk, Fredric Manfredsson, Anne Messer

    Alpha-synuclein (αSyn) aggregation and the formation of Lewy pathology (LP) is a foundational pathophysiological phenomenon in synucleinopathies. Delivering therapeutic single-chain and single-domain antibodies that bind pathogenic targets can disrupt intracellular aggregation. The fusion of antibody fragments to a negatively-charged proteasomal targeting motif (PEST) creates bifunctional constructs that enhance both solubility and turnover. With sequence-specific point mutations of PEST sequences that modulate proteasomal degradation efficiency, we report the creation of Programmable Target Antigen Proteolysis (PTAP) technology that can provide graded control over the levels of target antigens. We have previously demonstrated our lead anti-αSyn intrabody, VH14-PEST, is capable of reducing the pathological burden of synucleinopathy in vitro and in vivo. Here, we report a family of fully humanized VH14-PTAP constructs for controllable, therapeutic targeting of intracellular α-Syn. In cells, we demonstrate successful target engagement and efficacy of VH14-hPEST intrabodies, and validate proof-of-principle in human cells using 3D human organoids derived from PD-patient induced pluripotent stem cells (iPSC). In two synuclein-based rat models, PTAP intrabodies attenuated nigral αSyn pathology, preserved nigrostriatal dopaminergic tone, and slowed the propagation of αSyn pathology. These data demonstrate the potency of intracellular αSyn targeting as a method to alleviate pathology and highlight the potential clinical utility of PTAP intrabodies.